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ABSTRACT 
 
We have previously shown that partial inhibition of mitochondrial complex I activity 
with a small molecule tricycle pyrone compound (code name CP2) averted the 
development of cognitive and behavior phenotypes in multiple transgenic mouse models 
of Alzheimer’s disease (AD). One of the beneficial effects of CP2 involved the 
protection against oxidative stress in primary mouse neurons, human cells and in mice 
fed with a high fat diet. In the current study, I investigated the molecular mechanism of 
CP2-induced neuroprotection and established the translational potential of this 
therapeutics using murine, human and Drosophila model systems. Target identification 
revealed that CP2 competes with a flavin mononucleotide (FMN) for the binding to the 
redox subunit of mitochondrial complex I. Bioenergetics studies showed that CP2 mildly 
inhibits basal cellular respiration simultaneously leading to a dose-dependent generation 
of a sub-lethal level of reactive oxygen species (ROS). This increase in ROS rapidly 
activates cytosolic signaling pathways including the nuclear factor erythroid 2-related 
factor 2/antioxidant response element (NRF2/ARE) activation to induce a protection 
against oxidative stress. This retrograde response is known as mitohormesis, and the 
genetic validation of this phenomenon was done in the longevity studies in several 
model organisms including Drosophila and C. elegans. Mitohormetic nature of CP2-
induced protection against oxidative stress was confirmed using pharmacological and 
genetic manipulations in human cells, in Drosophila, and in the ARE reporter mice in 
vivo, and validated in mouse models of the AD. CP2 treatment also reduced the extent of 
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oxidative damage and enhanced the survival in wild-type (WT) mice fed with a high fat 
diet (HFD), which could be attributed to mitohormetic induction of the NRF2/ARE 
pathway. In summary, this study provides compelling evidence that mitohormetic 
activation of the NRF2/ARE pathway using small molecule partial inhibitor of 
mitochondrial complex I could be beneficial in multiple human conditions where 
oxidative stress contributes to the disease phenotype. 
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MAP2 Microtubule-associated proteins  
MDA Malondialdehyde 
mt-DNA Mitochondrial DNA 
mTOR Mammalian target of rapamycin signaling  
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
NF-κB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
NRF2 Nuclear factor erythroid 2–related factor  
OXPHOS Oxidative Phosphorylation 
PEG Polyethylene glycol 
PSEN1 Presenilin 1  
PSEN2 Presenilin 2  
 ix 
 
Rec-3 Renal epithelial cells  
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ROS  Reactive Oxygen Species 
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1. INTRODUCTION 
 
1.1. Etiology of Alzheimer’s disease 
 
Alzheimer's disease (AD) is the most common type of cognitive dysfunction, accounting 
for about 60% of all dementias [1]. AD is a devastating, progressive, age-related brain 
disorder that affected ~ 44 million people worldwide in 2015 [2]. It leads to the loss of 
neurons in brain regions involved in learning and memory including the temporal and 
frontal lobes.  
                     
AD is clinically characterized by progressive memory decline and other cognitive 
deficits, including impaired judgment, decision-making and language disturbances. 
Definitive diagnosis of AD requires postmortem examination of the brain and is made on 
the presence of “plaques” and “tangles” [3]. Plaques are extracellular deposits of fibrils 
and amorphous aggregates that include amyloid beta peptides (Aβ). In a healthy brain, 
these protein fragments are broken down and eliminated. In Alzheimer's disease, the 
fragments accumulate to form hard, insoluble plaques. Neurofibrillary tangles are 
intracellular fibrillary aggregates of hyper-phosphorylated microtubule-associated 
protein tau [4]. Along with the molecular pathology, reduction in synaptic density and 
neuronal loss in some specific brain regions, including the cerebral cortex and 
hippocampus, are also important criteria for the diagnosis of AD [5]. 
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The early-onset AD affects people ranging from 30-65 years of age and accounts for 
approximately 5% of total cases. It is associated with mutations in amyloid precursor 
protein (APP) [3], presenilin 1 (PSEN1) [4], and presenilin 2 (PSEN2), and is referred to 
as familial AD (FAD) [5]. However, most AD cases are sporadic with unknown genetic 
causes. Age is the greatest risk factor for the development of sporadic late-onset AD 
(LOAD). In recent years, extensive genetic evaluation identified risk factors for the 
development of LOAD where epsilon4 allele in Apolipoprotein (APOE4) gene is one of 
them [6]. Currently, AD has no cure. Lack of the detailed understanding of the disease 
mechanism hinders the development of efficacious therapeutic strategies. Therefore, the 
identification of early molecular mechanisms of AD and novel targets to halt the disease 
is of high priority. 
 
1.2. Amyloid cascade hypothesis 
 
Based on genetic etiology associated with the familial AD, the amyloid cascade 
hypothesis postulates that the neurodegeneration in AD is caused by abnormal 
accumulation of amyloid beta (Aβ) peptides in the brain [7]. Aβ is proposed to act as a 
pathological trigger for a cascade leading to the alterations in neuronal activity and 
synaptic loss caused by the formation of neurofibrillary tangles, which ultimately leads 
to neurodegeneration [7]. Aβ peptides, the major component of amyloid plaques, are 39–
43 amino acid residue peptides proteolytically derived from the sequential enzymatic 
secretase on widely distributed transmembrane amyloid precursor protein (APP) [8, 9]. 
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The length of Aβ peptide varies at C-terminal according to the cleavage pattern of APP.  
While cleavage of APP at the plasma membrane by the α-secretase occurs without 
formation of pathologic Aβ peptides, cleavage with β and γ-secretases leads to the 
release in the extracellular space of peptides with 40 or 42 residues which are prone to 
aggregation and represent the major component of extracellular amyloid plaques [10]. 
Further, the PS1 or PS2 mutations found in patients with FAD have specifically 
enhanced γ-secretase mediated cleavage to generate amyloidogenic Aβ42 peptides. 
However, the mechanism by which APP processing that leads to the formation of Aβ40 
or Aβ42 is triggered in sporadic AD patients is still not well understood and probably 
represents one of the most important missing links in the understanding of this 
devastating disease. Despite the extensive evidence to support Aβ-driven 
neurodegeneration, all strategies designed to reduce the production of Aβ by blocking 
the activity of β or γ secretases, preventing Aβ aggregation, or promoting Aβ clearance 
by immunotherapy have failed clinical trials emphasizing the urgent need for the 
development of new therapies for AD [11]. 
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1.3. Mitochondrial cascade hypothesis  
 
Although the amyloid cascade hypothesis provides a plausible explanation of the 
underlying pathogenesis of the familial form of AD, it does not explain the late-onset, 
sporadic type of the disease, which accounts for 95% of AD cases [12]. First, individuals 
affected with the sporadic form of AD generally lack mutations in the genes associated 
with APP processing (APP/PS1/PS2). Second, plaques are a relatively common finding 
in the non-demented elderly [13]. Therefore it is currently unclear what factors are 
responsible for AD in these sporadic cases. 
 
The mitochondrial cascade hypothesis asserts that mitochondrial function declining with 
age initiates pathological changes associated with AD and therefore represents the 
primary underlying problem in sporadic AD [12]. The initial validation of this 
hypothesis came from studying cybrid cell lines generated by fusing platelets from AD 
patients ( donor cells) with neuroblastoma SH-SY5Y cells (rho 0 cell) that were depleted 
of mitochondrial DNA (mtDNA). This process creates cytoplasmic hybrid (cybrid) cells 
where the mtDNA from the donor is expressed in the nuclear and cellular background of 
the host rho 0 cells. Differences in phenotype between disease and control groups can 
thus be attributed to the exogenous mitochondria and mtDNA. Indeed, AD cybrid cell 
lines showed compromised electron transport chain activity, elevated levels of free 
radical production and oxidative stress markers, altered calcium homeostasis, activated 
stress signaling pathways, reduced mitochondrial membrane potential, and an increase in 
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the level of Aβ40 and Aβ42 production compared to the cybrid cell lines with 
mitochondria from control subject [14, 15]. Further, it has been specifically shown that 
mitochondrial ROS was sufficient to induce the formation of Aβ plaques through the 
increased activity of β secretase and this effect was abolished when cells were treated 
with anti-oxidants, suggesting mt-ROS could explain the formation of amyloid plaques 
in the sporadic AD. Moreover, increased levels of Aβ could independently accelerate 
mitochondrial dysfunction contributing to further increase in production of Aβ forming a 
vicious cycle leading to synaptic dysfunction and memory loss [16] (Figure 1.1). 
 
 
 
Figure 1.1. Abnormal mitochondrial dynamics and function could trigger the 
development of late-onset sporadic AD.  
Reprinted from [17] 
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1.4. Oxidative stress is a major component of the underlying molecular mechanisms 
of AD 
 
One of the major outcomes of mitochondrial dysfunction is oxidative stress caused by 
increased production of ROS [18]. Oxidative stress contributes to the development of 
numerous human neurodegenerative diseases [19]. Oxidative stress is the result of the 
unregulated production of reactive oxygen species (ROS) including hydrogen peroxide, 
nitric oxide, superoxide and hydroxyl radicals. The brain is particularly susceptible to 
the oxidative imbalance due to its high energy demand, high oxygen consumption, and 
rich abundance of easily peroxidizable lipids [20]. About 90% of cellular ROS is 
produced during mitochondrial respiration via OXPHOS and the activity of the electron 
transport chain (ETC) located in the mitochondrial inner membrane where energy is 
generated in the form of ATP [21]. OXPHOS consists of five multi-heterogenic 
complexes. During respiration, electrons are transferred from NADH and FADH2 in the 
ETC via four membrane-bound complexes (complex I–IV) to oxygen, which finally 
generates water. As electrons are transported through complexes I, III, and IV, protons 
are pumped into the inner membrane space, generating an electrochemical gradient. This 
store of energy is used to generate ATP via the ATP synthase (complex V) (Figure 1.2). 
In this process, some electrons are leaking from the inner membrane and react with 
oxygen to form superoxide anions (O
2∙−
). This can further react to generate other forms 
of ROS such as hydrogen peroxide (H2O2), hydroxyl radicals (OH∙), and hydroxyl ions 
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(OH
−
). Reactive nitrogen species (RNS) are generated when O2
∙−
 reacts with nitric oxide 
(NO) to form peroxynitrite (ONOO
−
) [22].  
 
 
 
Figure 1.2. Oxidative phosphorylation machinery: Pathway for ATP generation 
and sites of ROS production in mitochondria.  
Reprinted from [17] 
 
Markers of oxidative stress including high levels of oxidized proteins, glycosylated 
products, extensive lipid peroxidation, formation of alcohols, aldehydes, free carbonyls, 
ketones, cholestenone, and oxidative modifications in RNA and nuclear and 
mitochondrial DNA were found in postmortem brain tissue and in peripheral cells and 
isolated mitochondria from people with preclinical or early stages of AD and ApoE4 
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carriers [17]. More recent studies showed significantly reduced activity of the 
antioxidant enzymes such as superoxide dismutase, glutathione peroxidase, and 
glutathione reductase in AD patients [23].  In another study, oxidative damage was 
reported to be the earliest event in AD followed by Aβ deposition [24]. Prevalence of 
oxidative damage in AD patients links the molecular chain of events initiated by 
mitochondrial dysfunction to AD pathology (Figures 1.1 and 1.2). Thus, it is feasible 
that inducing a protection against oxidative stress by activating intrinsic stress-response 
mechanisms that replenish the antioxidant cellular machinery could halt or reverse 
vicious cycle caused by mitochondrial dysfunction and delay the onset and/or slow the 
progression of AD (Figure 1.1).  
 
1.5. Mitochondrial complex I as a therapeutic target 
 
Cumulative evidence reveals that the regulation of mitochondrial turnover and function 
becomes impaired with ageing [25, 26]. Mitochondrial abnormalities include 
dysfunctional mitochondrial ETC activity, increased formation of ROS, shifted 
metabolic substrate utilization, aberrant mitochondrial dynamics (fission, fusion, axonal 
transport), and altered ion homeostasis [27]. Restoration of mitochondrial dynamics and 
function is currently considered as a therapy against many diseases [28]. However, 
strategies aimed to enhance mitochondrial activity via supplementation with the 
respiratory substrates or application of antioxidants failed in the clinical trials [29]. 
Unexpectedly, recent studies have shown that specific knock down of some genes 
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encoding for the subunits of complex I induce life-extension in worms and flies [30-33]. 
The increase in the lifespan has been attributed to mitohormetic ROS signaling that 
activates stress response. Moreover, analysis of the transcriptome of the long-lived 
species of N. Furzeri fish found a negative correlation between mitochondrial complex I 
activity and lifespan where pharmacological inhibition of complex I using a low dose of 
rotenone prolonged lifespan [34, 35]. An independent study using proteomics analysis 
demonstrated that low abundance of matrix arm subunits of complex I prolong life span 
in long-lived mice [36]. These studies further strengthen the fact that contrary to the 
increase in activity, partial inhibition of complex I through genetic or pharmacological 
means offsets ageing and could represent a drug target for age-related disorders. 
Furthermore, application of metformin, an FDA approved drug to treat diabetes, is also a 
partial mitochondrial complex I inhibitor, supports the safety of such approach in 
humans [37]. However, metformin does not penetrate the blood brain-barrier, and its 
application in AD models is controversial. 
 
1.6. Mitohormesis: a mechanism triggered by complex I inhibition 
 
To date, multiple studies have provided compelling evidence that partial inhibition of 
mitochondrial complex I increase longevity in model organisms including Drosophila, 
mice, C. elegans and N. Furzeri [38]. Investigations into the molecular mechanism 
behind this phenomenon revealed the presence of mitochondria-nuclear signaling where 
perturbations in mitochondrial function could be sensed by the nucleus leading to 
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changes in gene expression and chromatin remodeling [39]. This mito-nuclear 
communication helps the cell to maintain homeostasis under basal conditions and 
enables the adaptation to various stressors (Figure 1.3). Under mild stress conditions, 
mitochondria send “signals of distress” inducing a nuclear response that reconfigures 
cellular metabolism allowing the production of essential energy substrates and stress 
enzymes that provide both short-term cellular benefits and potential long-term 
adaptation [40, 41]. This phenomenon of non-lethal mitochondrial inhibition that 
stimulates stress response mechanism is known as mitohormesis. For example, 
beneficial effects of calorie restriction and exercise were explained by mitohormetic 
positive adaptation to stress induced by the transient generation of ROS in mitochondria 
[42]. ROS has been defined as the major signaling molecule of the mitohormesis, which 
is generated during inhibition of electron transport chain. While high levels of ROS are 
generally accepted to cause cellular damage and to promote ageing, low, sub-lethal 
levels of ROS serve as signaling molecules essential for many normal cellular functions 
[43]. The final validation of the beneficial effect of ROS came from studying the 
lifespan of C. elegans and Drosophila where the life-extending effects induced by calorie 
restriction or RNAi-mediated knockdown of mitochondrial complex I subunits were 
blocked by antioxidants [44-46]. The downstream signaling cascade associated with 
transiently increased ROS levels includes activation of p38, mitogen-activated protein 
(MAP) kinase, the transcription factors such as hypoxia-induced factors (HIF), 
antioxidant enzymes of unfolded protein response (UPR), innate immunity, autophagy, 
mitochondrial biogenesis, etc., which overall leads to better efficiency of cellular 
 11 
 
functions, better clearance and turnover of aggregated proteins including A and 
damaged mitochondria, and enhanced cellular energetics  [40, 47, 48]. Together, these 
studies suggest that pharmacological agents that could trigger mitohormesis could 
provide alternative therapeutic strategies to promote healthy ageing and mimic the effect 
of caloric restriction and exercise.  
 
 
 
 
Figure 1.3. Multiple factors activate mitohormetic response.   
Sub-lethal mitochondrial stress including ETC inhibitors, exercise, hypoxia, calorie 
restriction, and impaired glucose utilization through altered insulin growth factor-1 
(IGF-1), activates signaling cascade leading to nuclear response known as mitohormesis. 
Mitohormesis provides adaptation to mild level of stress by increasing the production of 
respiratory substrates, activating autophagy and immunity, enhancing mitochondrial 
biogenesis and UPR activation. 
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1.7. Activation of the NRF2 pathway in neuroprotection   
 
One of the most important outcomes of mitohormetic response is the activation of the 
transcription factor nuclear factor erythroid 2–related factor (NRF2) from the leucine 
zipper family [42]. NRF2 is a transcription factor and is the major regulator for the 
expression of over 200 genes that contain in their promoters the antioxidant response 
element (ARE) (Figure 1.4). These genes participate in phase I, II and III detoxification 
reactions, glutathione and peroxiredoxin/thyoredoxin metabolism, NADPH production, 
fatty acid oxidation, iron metabolism, proteasomal and autophagic processes, and gene 
regulation of other transcription factors [49]. NRF2 is tightly controlled at the level of 
protein stability by the ubiquitin E3 ligase adapter Kelch-like ECH-associated protein 1 
(KEAP1). KEAP1 is a homodimeric E3 ligase adapter that contains several electrophilic 
and redox-sensitive cysteine residues. Under basal redox conditions, KEAP1 binds one 
molecule of NRF2 at two amino acid sequences with low (aspartate, leucine, glycine; 
DLG) and high (glutamate, threonine, glycine, glutamate; ETGE) affinity, respectively, 
and presents NRF2 to a complex formed by Cullin3/Rbx proteins leading to its 
ubiquitination and subsequent proteasomal degradation [50].  
 
However, ROS and electrophiles are able to modify sulfhydryl groups of specific redox-
sensitive cysteines of KEAP1, including C151, C273, and C288 [51]. Following these 
modifications, KEAP1 is no longer capable of presenting this protein for ubiquitination 
[52]. As a result, NRF2 escapes KEAP1-dependent degradation, accumulates in the 
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nucleus, and activates the expression of ARE genes. Several studies have suggested a 
KEAP1-independent mechanism for NRF2 activation that includes a direct 
phosphorylation of NRF2 mediating its translocation to the nucleus [53, 54].   
 
 
 
Figure 1.4. Mechanism of the NRF2 activation.  
Under basal conditions, NRF2 is bound to KEAP1 and CUL3, which act as adaptors for 
ubiquitination followed by proteasomal degradation. In the presence of ROS, 
electrophiles or kinases, the cysteine residues of KEAP1 are modified that breaks the 
interaction between NRF2 and KEAP1 thereby facilitating NRF2 translocation to the 
nucleus initiating a transcription of the ARE genes.  
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Several important findings connect NRF2 to AD mechanisms. In hippocampal neurons 
of AD patients, NRF2 is predominantly cytoplasmic, suggesting the impaired capacity of 
these neurons to reduce proteotoxic and oxidative stress through NRF2-dependent 
transcription of cyto-protective genes. NRF2 overexpression in vitro protects against 
neurotoxicity of Aβ peptides and is associated with increased expression of NRF2 target 
genes and reduced oxidative stress [55].  Lentiviral overexpression of NRF2 in the 
hippocampus of old mice expressing mutant APP and PS1 transgenes was able to 
prevent spatial learning deficits [55]. Moreover, studies in NRF2-/- mice have shown the 
presence of amyloidopathy or tauopathy hallmarks [56, 57]. Hence, even in the absence 
of human transgenes involved in FAD,  lack of the NRF2 expression in  NRF2-/- mice 
resulted in the development of cognitive deficit that correlated with spontaneous tau 
aggregation [58]. Activation of the NRF2 pathway reduced levels of phosphorylated tau 
via induction of an autophagy adaptor protein calcium binding and coiled-coil domain 2 
(CALCOCO2) in neurons [58]. Recently, a new mechanism of direct inhibition of 
inflammation by NRF2 has been reported, in which NRF2 activation suppresses 
macrophage and microglia inflammatory response by blocking the expression of pro-
inflammatory cytokine genes such as Interleukin-6 (IL-6) and repressing transcriptional 
activity of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) [59, 
60]. Altogether, this data strongly suggest that NRF2 deficiency exacerbates oxidative 
stress, neuro-inflammation and protein aggregation, the major pathways involved in AD 
pathophysiology (Figure 1.1). Moreover, antioxidant therapy based on the up-regulation 
of NRF2 has several important advantages over antioxidant supplementation since NRF2 
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activation will enhance the endogenous antioxidant metabolism (NADPH, Glutathione, 
and thioredoxin) in local places where needed while leaving physiological ROS 
signaling intact.  
  
 
 
 
 
 
 
 
 
Figure 1.5. NRF2 provides neuroprotection via multiple pathways.  
NRF2 initiates the transcription of genes that mediate oxidative stress response, 
proteasomal degradation of proteins and autophagy process thereby reducing Aβ and 
Tau aggregates. NRF2 also suppresses the production of pro-inflammatory cytokines 
from microglia and macrophages reducing inflammation and neurotoxicity. 
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Figure 1.6. Hierarchical oxidative stress model.  
A low oxidative stress induces NRF2, a transcription factor implicated in the activation 
of the expression of genes coding for antioxidant enzymes. An intermediate amount of 
ROS triggers an inflammatory response through the activation of NF-κB and AP1, and a 
high amount of oxidative stress induces apoptosis.  
Reprinted from [61].  
 
 
It is important to note that depending on the level of ROS, different redox-sensitive 
transcription factors are activated and coordinate distinct biological responses as shown 
in Figure 1.6. A low oxidative stress induces activation of a transcription factor NRF2 
implicated in the activation of genes coding for antioxidant enzymes. An intermediate 
amount of ROS triggers an inflammatory response through the activation of NF-κB 
(nuclear factor kappa-light-chain-enhancer of activated B cells) and AP1 (Activator 
protein 1), and a high level of oxidative stress induces perturbation of the mitochondrial 
permeability transition pore and disruption of the electron transfer, thereby resulting in 
apoptosis or necrosis. Since mitohormesis is mediated by low level of ROS, hence it 
should only involve the activation of NRF2 signaling pathway, not the other 
transcriptional factors that are activated at high ROS level like NF-κB and/or AP1 and 
must not induce any toxicity 
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1.8. Small molecule complex I inhibitor CP2 induces neuroprotection in AD  
 
Failure of recent clinical trials that targeted Aβ production and clearance indicates that 
amyloidopathy alone provides an incomplete view of disease urging the need for a 
discovery of new drug targets for AD. In the previous study, we demonstrated that 
partial inhibition of mitochondrial complex I with a small molecule CP2 induced 
neuroprotection preserving cognitive function in multiple mouse models of familial AD 
when independent cohorts of APP, PS1, and APP/PS1 mice were treated in utero, at pre- 
or symptomatic stages of the disease [62]. Partial inhibition of complex I is known to 
prolong the lifespan in multiple model organisms [35, 36]. However, our study was the 
first to show that this approach could be beneficial in AD. Extensive mechanistic and 
target identification studies revealed that CP2 penetrates the blood brain barrier, and 
accumulates in mitochondria where it competes with the flavin mononucleotide (FMN) 
for binding to the redox center of complex I [62, 63]. Molecular mechanisms induced by 
partial inhibition of complex I activity using CP2 included activation of AMP-activated 
protein kinase (AMPK); increased mitochondrial biogenesis and enhanced cellular 
energetics; increased autophagy and a reduction of soluble and insoluble levels of A 
and pTau; inhibition of the activity of glycogen synthase kinase 3β (GSK-3β), 
restoration of axonal trafficking, increased levels of brain-derived neurotrophic factor 
(BDNF) and synaptic proteins. Interestingly, it was also found that CP2 induces a 
protection against oxidative stress in primary mouse neurons (Figure 1.7 A). In order to 
demonstrate a translational potential of this mechanism, experiments with human 
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neuronal cells derived from induced pluripotent stem cells were conducted in the 
laboratory of Dr. Carman at InVitro Cell Research, LLC, Englewood, NJ.  It was found 
that CP2 also protected against oxidative stress in human neuronal cells. (Figure 1.7 B).  
 
 
 
 
Figure 1.7. CP2 protects against oxidative stress in primary mouse neurons (A) and 
in human neuronal cells (B). 
Cells were treated with 0.5 – 5 µM CP2  (A) or 0.5 – 20 µM of CP2 (B) for 24 hours, 
followed by treatment with 1 mM H2O2 for 2 hours followed with the measurement of 
cell survival. Figure (A) Reprinted from [62]. 
Figure (B) obtained from the unpublished results of Dr. Carman laboratory, InVitro Cell 
Research. 
 
Furthermore, in order to validate that CP2 could protect against oxidative stress in vivo 
Trushina’s lab examined a survival of WT mice fed with a high fat diet (HFD). HFD 
treatment represents an established in vivo model of oxidative stress where animals 
develop multiple tumors and die prematurely. Two groups of one-year old WT female 
A B 
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mice, ten animals in each group, were treated either with a HFD or with a HFD + CP2 
(25 mg/kg/day via drinking water ad lib) till 2.5 years of age. It was found that CP2 
treated mice fed with a high fat diet demonstrated enhanced health and life span (Figure 
1.8). All animals in a HFD group developed multiple tumors confirmed during the 
postmortem tissue examination while none of the animals in HFD+CP2 group developed 
tumors. 
 
 
 
Figure 1.8.  CP2 promotes a survival in WT mice fed with a HFD.  
CP2 treatment (25mg/kg/day via drinking water ad lib) induces a protection against 
oxidative stress in WT mice fed a HFD. Survival of mice on CP2 was compared to 
vehicle-treated mice (n=10 in each group). 
Figure obtained from the unpublished results of Dr. Trushina’s and Dr. Chini laboratory, 
Mayo Clinic. 
 
Since CP2 partially reduces complex I activity and mitochondrial respiration, it was 
examined whether CP2 leads to a generation of ROS in mitochondria isolated from 
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mouse brain tissue. These experiments were conducted in collaboration Dr. Galkin, Weil 
Cornell, NY. At CP2 concentrations previously shown efficacious for protection against 
oxidative stress in vivo and in vitro (> 20 µM), it was confirmed that CP2 partially 
inhibited mitochondrial respiration in agreement with our previous studies [67]. It was 
also found that at these concentrations CP2 produced a low level of ROS (Figure 1.9), 
which could act as signaling molecules for various transcriptional factors.  
 
 
Figure 1.9. CP2 induces a dose-dependent inhibition of respiration and an increase 
in ROS levels in mitochondria isolated from the mouse brain tissue.  
Mitochondria isolated from the mouse brain tissue were used for measurement of ROS 
production and respiration after CP2 treatment (0 - 60 µM). Two individual 
mitochondrial preparations were used for experiments, and each data point represents a 
mean of three independent measurements. 
Figure obtained from the unpublished results of Dr. Galkin laboratory, Weil Cornell.  
 
 
My project was focused on dissecting the molecular mechanism of CP2-induced 
protection against oxidative stress using multiple model systems. Detailed investigation 
CP2, µM 
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of the molecular mechanism involved in this phenomenon could advance the 
understanding of the fundamental mechanisms of stress resilience induced by 
mitochondria and aid the development of novel therapeutic strategies applicable to 
multiple human conditions. 
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2. RESEARCH AIMS 
 
The overall goal of this study was to determine the molecular mechanism involved in a 
protection against oxidative stress induced by partial inhibition of mitochondrial 
complex I with a small molecule CP2.  
 
2.1 Specific Research Aims 
 
Aim 1. Investigate the molecular mechanism of CP2-induced protection against 
oxidative stress 
1.1. Examine whether CP2 is an antioxidant. 
1.2. Examine whether partial inhibition of mitochondrial complex I using CP2 
induces the NRF2 activation via mitohormesis in vitro and in vivo. 
Aim 2. Using genetic manipulations in Drosophila, confirm that NRF2 activation is 
essential for a CP2-induced protection against oxidative stress. 
Aim 3. Validate that enhanced survival found in CP2-treated wild-type mice fed with a 
high fat diet was linked to the reduction of oxidative damage.  
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3. MATERIAL AND METHODS 
 
3.1. Cells 
 
ARE HEPG2, AP1 HEK293, and NF-κB HEK293 reporter cells were purchased from 
BPS biosciences (Catalog# 60513, 60405, and 60650 respectively).  
 
3.2. Animals 
 
Animal care and handling procedures were approved by the Mayo Clinical Institutional 
Animal Care and Use Committee in accordance with the National Institutes of Health’s 
Guide for the Care and Use of Laboratory Animals. Drosophila strains were purchased 
from Bloomington Drosophila Stock Center at Indiana University include female 
elavGal4 (8760) and male attp2 (36303), NRF2 RNAi (25984). All flies were kept at 
25°C. Control or NRF2 RNAi Drosophila lines were created by crossing elavGAL4 
virgin females with attp2 or NRF2 RNAi males. For studies with mice fed a high- fat 
diet, C57Bl6 retired female breeders were purchased from Jackson’s laboratory. CP2 
treated ARE reporter mice brain tissue samples were provided by Dr. Michael Lee, 
University of Minnesota. 
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3.3. Reagents 
 
CP2 was synthesized by Nanosyn, Inc using method described by Hua et al. (2003) and 
purified using HPLC. Neurobasal medium (Gibco, catalog# 21103-049), B27 
supplement (Gibco, catalog# 17504-044), Glutamine (Gibco, catalog# 25030-032), 
penicillin-streptomycin (Penstrep, sigma, catalog# PO781), Poly-L-ornithine (Sigma, 
catalog# P3655), DMEM high glucose, 25 mM HEPES, no glutamine (Lonza, catalog# 
12-709B), F-12 (Gibco, catalog# 11765-054), Serum, iron supplemented bovine calf 
serum (HYC, catalog# 2049), papain (Worthington, catalog# LK003176), mitosox 
(Thermo scientific, catalog# M36008) 
 
3.4. CP2 preparation and treatment 
 
For in vitro studies, CP2 was dissolved in polyethylene glycol (PEG) or 100% DMSO at 
final concentration of 50 mM. For experiments involved in treatment of the ARE 
reporter mice, CP2 was gavaged at a concentration of 25 mg/kg/day. For experiments 
with Drosophila, CP2 was mixed with 20% sucrose diet at concentration of 25 
mg/kg/day.  
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3.5. Primers 
 
The following primers were used for the quantification of the NRF2 homolog, 
cap'n'collar subfamily of leucine zipper (Cncc) expression levels in Drosophila. Primers 
were designed using NCBI primer designing tool. They were dissolved in dd H2O2 to 
obtain 10  final concentrations.  
Forward primer Cncc: GTTTTCAAGCTCACCACCAAT 
Reverse Primer Cncc: AAATTCGCAGTTTCCACGGC 
 
3.6. Cell culture 
 
HEPG2 ARE reporter cells and were cultured in the rich MEM low glucose complete 
media (Corning, catalog# 10-010CV) supplemented with 10% FBS (sigma, catalog# 
2442), sodium pyruvate (Corning, catalog# MT25000CI), MEM non-essential amino 
acids (Corning, catalog# 25-025-CI).  
 
3.7. Luciferase assay 
 
HEPG2 ARE reporter cells were seeded in 96 well plates at a density of 30,000 cells per 
well and cultured for 24 hours. Cells were treated with 2.5 to 20 µM CP2 dissolved in 
PEG, followed by 24 hours incubation. Cells were washed with PBS and lysed in 30 µl 
of lysis buffer (50 mM Tris, 2.5 mM EDTA, 150 mM NaCl, 1% Triton and 0.25% of 
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NP-40). Luciferase activity was measured using Promega kit (Catalog# E1960). 100 µl 
of the substrate was added to 25 µl of lysate and luminescence was measured in 
luminometer with 500 ms integration time. Protein quantification was done to normalize 
the luminescence using BCA protein quantification kit (Bio-Rad, catalog# 500012) by 
measuring the absorbance at 750 nM.  
 
3.8. Measurement of ROS levels in HEPG2 ARE reporter cells 
 
ROS generation was measured in HEPG2 ARE reporter cells using mitosox (Thermo-
scientific, catalog# M36008), which is a red mitochondrial superoxide fluorescent 
indicator. HEPG2 ARE reporter cells were seeded at a density of 0.5 million cells per 
well in 6 well plate and cultured overnight. There are two assays to measure ROS. First 
experiment demonstrate whether CP2 leads to ROS generation in HEPG2 ARE reporter 
cells, in which cells were treated with 5 µM mitosox in HBSS buffer for 10 min at 37°C, 
followed by 20 µM CP2 treatment for 1.5 hours. In the other experiment to determine at 
which time point of CP2 incubation, ROS production occurs, cells were treated with 20 
µM CP2 or 50 µM antimycin for 5 min, 15 min, 45 min and 1 hour, media was removed 
and 5 µM mitosox in HBSS buffer was added for 10 min incubation at 37°C. In both the 
experiments, cells were trypsinised, collected in PBS + 5% FBS, and analyzed by flow 
cytometry at 488 nM excitation/580 nM emission wavelength. Results were analyzed 
using Cell quest software (BD Biosciences) 
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3.9. Cell viability assays 
  
Cells were treated with 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide 
(MTT) reagent at 0.25 mg/ml followed by 4 hours of incubation at 37°C. Solubilization 
of MTT formazan was done by the addition of 200 µl of 40 nM HCl in isopropanol (2:1) 
to 100 µl of media for 10 min placed on a shaker, and absorbance was measured at 570 
nM.  
 
3.10. Quantitative PCR 
 
To test for the m-RNA expression of NRF2 in the WT and NRF2 RNAi cross, one step 
q-PCR SYGR kit (Bio-Rad, catalog# 1725150) was used. Ribosomal subunit-49 (RP-49) 
was used as housekeeping gene for normalization. Samples were run in thermocycler in 
triplicates with following conditions: 10 min at 50°C (reverse transcription), 1 min at 
95°C (polymerase activation), followed by 38 cycles of denaturing and annealing/ 
extension for 10 sec at 95°C and 30 sec at 60°C respectively. The data were analyzed by 
double delta Ct analysis. 
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3.11. Human placental alkaline phosphatase activity in ARE reporter mice 
 
ARE activation after CP2 treatment was measured in vivo using ARE reporter mice by 
the quantification of human placental alkaline phosphatase (hPAP) enzyme activity in 
brain tissue collected after 4 days of CP2 treatment (gavage with CP2 25 mg/kg/day in 
PEG). Two to five mg frozen hippocampus brain tissue was homogenized in 1 mL 
TMNC buffer (50 mM Tris pH 7.5, 5 mM MgCl2, 100 mM NaCl, and 4% 3-((3-
cholamidopropyl) dimethylammonio)-1-propanesulfonate (CHAPS)). The homogenate 
was freeze-thawed, and 25 μL of lysate was added to a white-walled 96 well plate and 
mixed with 75 μL of 200 mM diethanolamine (DEA) buffers. Plates were incubated for 
20 min at 65°C to inhibit endogenous phosphatases. Following the addition of 100 μL of 
substrate solution [2X CSPD (Applied Biosystems, catalog# T2041), 2X Emerald 
reagent (Applied Biosystems, catalog# T2115), 5 mM MgCl2, and 150 mM DEA] and 
incubation in the dark for 20 min at room temperature, luminescence was measured 
using a microplate luminometer (Berthold Detection Systems, Pforzheim, Germany) 
with one second integration time. Luminescence values were normalized to protein 
concentration measured using bicinchoninic acid protein assay (Bio-Rad, catalog# 
500012). ARE-hPAP activity was expressed as relative luminescence units (RLU) per 
mg of protein. 
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3.12. Estimation of lipid peroxidation 
 
Lipid peroxidation was estimated by measuring the amount of malondialdehyde (MDA) 
using a calorimetric assay (Sigma, catalog# MAK085-1KT). 5 mg of the cortex and 
hippocampus tissues were isolated from WT mice fed with a high-fat diet from control 
(HFD alone), and CP2 treated mice (HFD+CP2) and were lysed in 300 µl of the MDA 
lysis buffer, centrifuged, and supernatant was transferred to another tube. 200 µl of 
sample or standard were aliquoted in different tubes, and 600 µl of 2-thiobarbituric acid 
(TBA) was added to each tube. The rest of the sample was diluted 5 times in lysis buffer 
for protein estimation (3 µl in 12 µl of lysis buffer). Samples were incubated for 1 hour 
at 95°C, centrifuged at 2000 g for 1 minute and the supernatant was separated. 200 µl of 
the adduct solution was added to each well of clear 96 well plate. Absorbance was read 
at 532 nM wavelength. Absorbance values were blank corrected and normalized for 
protein concentration. 
 
3.13. Assessment of a total CP2 anti-oxidant capacity 
 
To analyze the anti-oxidant capacity of CP2, I followed instructions provided in total 
antioxidant capacity assay kit (Sigma, catalog# MAK187). The quantification is based 
on the reaction where reduced Cu
+
 ion chelates with a colorimetric probe giving a broad 
absorbance peak at ~570 nm, which is proportional to the total antioxidant capacity. 
Various concentrations of a strong anti-oxidant trolox (4 - 20 µM/well) were used as 
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positive control. Further, 100 µL of Cu
2+
 working solution to both CP2 and trolox was 
added. Samples were incubated at room temperature for 90 min followed by absorbance 
measurement. 
 
3.14 Neuronal culture from embryonic day 17 (E17) mice 
 
Following reagents were prepared a day before neuronal culture in molecular grade 
water. 
1. Hepes buffered Saline (HBS) (0% Ca2+ - 0% Mg2+). For 500 ml: 
1.1. 4.2g NaCl  
1.2. 0.112g KCl 
1.3. 1.19g HEPES 
1.4. 0.5g glucose 
1.5. pH was adjusted to 7.3 with 1 N NaOH 
1.6. Solution was filtered sterile and stored at 4°C 
 
2. Borate Buffer (500 ml): 
2.1. 2.38g boric acid 
2.2. 1.27g borax (sodium borate) in 400 ml H2O 
2.3. pH was adjusted to 8.4 and volume to 500 ml  
2.4. Solution was filtered sterile and stored at 4°C 
3. Poly-L-Ornithine: 0.5 mg/ml in borate buffer was prepared. 
4. Papain solution: 2mg/ml in HBS was prepared. 
 
5. Plating media : 
5.1. 400 ml DMEM 
5.2. 50 ml heat inactivated bovine calf serum. FBS was thawed at 56°C for 30 
mins and swirled every 10 min, followed by 10 min incubation on ice and 
aliquoted to 50 ml tubes. 
5.3. 50 ml F-12 
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5.4. 1 ml Penstrep 
5.5. Solutions were mixed and aliquoted into 50 ml conical tubes under sterile 
conditions and stored at 4°C. 
 
6.  Feeding media 
6.1. 500 ml neurobasal media 
6.2. 10 ml B27 supplement  
6.3. 1 ml PenStrep 
6.4. 125 μl of glutamine (200 mM) must be added prior to each feed to the 
individual 50 ml conical tubes 
6.5. Solutions were mixed and aliquoted into 50 ml conical tubes under sterile 
conditions and stored at 4°C. 
 
 
3.14.1. Procedure before dissection 
1. Poly-L-Ornithine coating: 10 ml of 0.5 mg/ml of Poly-L-Ornithine in borate buffer 
was used to cover 10 cm dish and left overnight under the hood. 
2. On the day of neuronal culture, Poly-L-Ornithine was aspirated with sterile pasteur 
pipette and washed 2x with sterile water. 
3. Dishes were left under the hood to dry for 2-4 hours without lids. 
4. Once dried, plate was covered with 10 ml of platting media and left in incubator 
until neurons were isolated for plating. 
 
3.14.2. Preparation for dissection 
1. All the dissecting instruments were sterilized in gauze at bottom, filled with Ethanol. 
2. HBS was aliquoted into three 100 mm petri dishes and one 35 mm dish. 
3. Plating medium was placed in 37°C water bath and 0.25 ml papain was aliquoted 
was placed inside hood in 15 ml tube. 
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3.14.3. Procedure to sacrifice the mouse 
All procedures involving animals were approved by the Institutional Animal Care and 
Use Committee. All efforts were made to minimize animal suffering and to reduce the 
number of animals used.  
1. Cervical dislocation method was used on the wild type murine pregnant mother at 
gestational day 17. 
2. To sterilize and prevent hair contamination, mouse was placed on its back and 
ethanol was spared on the abdomen of the mouse until all hair gets wet. 
3. Grabbing the abdominal muscle with the forceps a transversal incision was made. By 
inserting one of the blades of the scissors into the abdominal cavity a longitudinal 
incision was made to expose abdominal content.  
4. Vagina was cut and uterus containing 17 days old embryo was removed and placed 
in 10 cm plate containing HBS buffer. 
3.14.4. Extraction of brain tissue 
1. With scissors, embryos were released from the placenta and then moved with the 
spoon to 10 cm petri dish with sterile HBS. 
2. In the same dish, heads were cut and with the spoon, transferred into another 10 cm 
dish with HBS. This maintains cleaner conditions, which ensures maintaining sterile 
conditions for neuronal culturing. 
3. To dissect the brain, tweezers were used to hold the head, and brain was exposed 
using the snip between the eyes and the back of the head to peel the top of the head. 
4. Isolated brain was transferred to the second 10 cm petri dish with sterile HBS.  
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5. Forceps were used to split the hemispheres, and using olfactory blub as a landmark, 
meninges were removed. Further, hippocampus was also removed exposing the 
intact cortical tissue.  
6. Cortex was clipped using forceps and collected into another 35 mm dish. 
 
3.14.5. Neuronal cell plating 
1. Once the cortex was collected from all hemispheres, tissue was transferred to the 15 
ml conical tube containing papain solution using the sterile plastic pipette and 
incubated at 37°C for 20-30 min. 
2. After papain digestion, cortex was transferred into 10 ml of plating media and 
homogenized using 1 ml pipette ~ 20 times.  
3. Live neurons were counted using trypan blue on hemocytometer and cells were 
platted at a density of 35,000 cells per ml and kept in incubator at 37°C. 
4. After 72 hours, media was changed to feeding media, which was supplemented with 
L-glutamine and cells were kept in incubator at 37°C for next 3 – 4 days. 
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4. RESULTS 
 
4.1. CP2 does not possess anti-oxidant properties  
 
In order to dissect the molecular mechanism of oxidative stress protection induced by 
CP2, I first determined whether CP2 has anti-oxidant properties. The total non-
enzymatic anti-oxidant capacity of CP2 was accessed using a calorimetric assay kit 
(sigma, catalog# MAK187-1KT) that measures a reduction of the cupric ion to cuprous 
ion. I used this kit to determine whether 2.5 – 100 µM of CP2 could reduce Cu2+ to Cu+.  
Cu
+
 chelates with a colorimetric probe and gives a broad absorbance peak at ~570 nm 
indicative of the total anti-oxidant capacity. Trolox, a known anti-oxidant, was used as a 
positive control.  Trolox or CP2 were diluted to concentrations ranging from 0, 2.5, 10, 
20, 50, and 100 µM in 100 µl of water in a clear 96 well plate. Two vehicle controls 
included PEG for CP2 and DMSO for trolox, respectively. 100 µl of solution containing 
Cu
2+
 working solution + probe was added to each well containing either CP2 or trolox 
samples and mixed by multiple pipetting. Plate was incubated in dark for 90 minutes at 
room temperature followed by absorbance measurement at 570 nM on a 96 well plate 
reader. Experiments were done in triplicates; data was plotted as mean +/- standard 
deviation. I found that CP2 does not behave as an anti-oxidant at concentrations ranging 
from 2.5 µM to 100 µM (Figure 4.1). I observed a small increase in absorbance at high 
concentrations of CP2 that, most likely, was due to its precipitation.  
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Figure 4.1. CP2 does not behave as an anti-oxidant.   
Total non-enzymatic antioxidant capacity of CP2 compared to trolox was measured by 
quantifying the reduction of Cu
2+
 to Cu
+
. Cu
+ 
chelates with a colorimetric probe 
produces an absorbance peak at ~570 nm, which corresponds to a total antioxidant 
capacity. Graph is representative of two independent experiment and data is represented 
as mean +/- SD of triplicates; t-test was used for statistics, ****, p < 0.001. 
 
4.2. CP2 specifically induces the NRF2 activation in HEPG2 reporter cells  
 
Sub-lethal levels of ROS could facilitate mitochondria-nuclear communication via 
mitohormetic activation of protective mechanisms. From data generated with our 
collaborators, we learn that at concentrations of 0 - 20 µM, CP2 generates low dose of 
ROS in mitochondria isolated from mouse brain tissue. Depending on the levels, ROS 
are known to activate many transcriptional factors including NRF2, NF-κB and AP1.  In 
order to confirm what pathways were activated after CP2 treatment, I tested the effect of 
CP2 on luciferase activity in NRF2 HEPG2 (BPS bioscience, catalog# 60513), AP1 
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HEK293 (BPS bioscience, catalog# 60405) and NF-κB HEK293 (BPS bioscience, 
catalog# 60650) reporter cell lines. These reporter cell lines stably expressed the 
luciferin gene tagged with an upstream binding sequence for NRF2, AP1 or NF-κB 
transcription factor. In order to perform these experiments, cell density for reporter cells 
was optimized for seeding in the 96 well plate, and 35,000 cells per well was found to be 
ideal. CP2 doze optimization was also done to determine its physiological concentrations 
in both HEPG2 and HEK293 reporter cell lines using the MTT assay. For MTT assay, 
30,000 cells were seeded in 96 well plates following with the overnight incubation in 
rich MEM media. Next day, cell survival was measured using the MTT assay. It was 
found that CP2 did not induce any toxicity in HEPG2 reporter cells or HEK293 reporter 
cells at concentration up to 50 µM (Figure 4.2 A, B). Hence, I proceeded with using 0 - 
20 µM of CP2 for the luciferase assay.  
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Figure 4.2. CP2 does not induce toxicity in HEPG2 (A) or HEK293 (B) reporter 
cells below 50 µM. 
HEPG2 or HEK293 reporter cells were treated with 0 – 100 µM of CP2 for 24 hours 
followed by measurements of cell survival using the MTT assay. Both the graphs 
represent two independent experiments; data is presented as the mean +/- SE of five 
replicates.  
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For the measurement of luciferase activity, cells were incubated with different 
concentrations of CP2 (2.5 µM - 20 µM) dissolved in PEG; 10 µM sulforaphane used as 
a positive control (NRF2 activator); or 10 ng/ml of phorbol 12-myristate 13-acetate 
(PMA, a known NF-κB and AP1 activator); or PEG alone as a negative control for 8, 24 
and 48 hours in 3 replicates. Cells were observed under the microscope for each well 
after respective incubation time, and no cell death was observed in cells treated with 
vehicle, CP2 or positive controls. Flow chart of experimental procedure is presented in 
Figure 4.3. After the incubation, cells were washed with PBS and lysed in 30 µl of lysis 
buffer. 25 µl of lysate was treated with luciferase chemiluminescent substrate, and 
luminescence was measured in a plate reader with 500 ms time of integration. 
Remaining 5 µl of the lysate was used for the protein quantification using the BCA assay 
(Bio-Rad # 500012), where standards were prepared in the same buffer as was used for 
cell lysis. Luminescence data was normalized by protein concentration for each well. I 
found that CP2 leads to the activation of NRF2 after 24 hours of incubation, which 
sustained till 48 hours (Figure 4.4). However, I also found that CP2 did not induce the 
activation of AP1 and NF-κB after 8, 24 or 48 hours (Figure 4.5 and 4.6). This signifies 
that CP2 leads to the generation of low ROS that is sufficient to activate NRF2 but not 
NF-κB and AP1 signaling pathways consistent with the mitohormetic mechanism. I 
observed that CP2 reduced AP1 and NF-κB activity, which could be due to the negative 
feedback signaling of NRF2 activation [61]. These results suggested that CP2 
specifically activates NRF2 at concentration below the toxicity levels in reporter cells. 
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Figure 4.3. Experimental procedure to measure the luciferase activity in reporter 
cells. 
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Figure 4.4. CP2 induces NRF2 activation in HEPG2 reporter cells. 
NRF2 activation was measured after 2.5 µM- 20 µM CP2 treatment for 8 (A), 24 (B) 
and 48 (C) hrs using luciferase assay in HEPG2 reporter cells. Luminescence data was 
normalized to the protein concentration. All graphs represent data from three 
independent experiments. Data is presented as mean +/- SE of 3 replicates; t-test is used 
for the statistics, **, p <0.01;***, p < 0.005 
 
A B 
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Figure 4.5. CP2 does not induce NF-κB activation in HEK293 reporter cells. 
NF-κB activation was measured after 2.5 µM- 20 µM CP2 for 8 (A), 24 (B) and 48 (C) 
hrs treatment using luciferase assay in NF-κB HEK293 reporter cells. Luminescence 
data was normalized to the protein concentration. All graphs represent data from three 
independent experiments. Data is presented as mean +/- SE of triplicates; t-test is used 
for the statistics, **, p <0.01;***, p < 0.005 
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Figure 4.6. CP2 does not induce AP1 activation in HEK293 reporter cells. 
AP1 activation was measured after 2.5 µM- 20 µM CP2 treatment for 8 (A), 24 (B) and 
48 (C) hrs using the luciferase assay in AP1 HEK293 reporter cells. Luminescence data 
was normalized to the protein concentration. All the graphs shown are the representative 
of three independent experiments. Data is presented as mean +/- SE of triplicates; t-test 
is used for the statistics, **, p <0.01;***, p < 0.005 
 
 
 
B 
A 
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4.3. CP2 treatment induces mild ROS production, which is consistent with 
mitohormetic mechanism  
 
Since it is known that CP2 leads to a partial inhibition of respiration and mild ROS 
production at concentrations below 20 µM in isolated mitochondria (Figure 1.9), I 
examined if CP2 induces ROS production in HEPG2 reporter cells. For the measurement 
of ROS in reporter cells, 0.5 million cells were seeded in 6 well plate in rich MEM 
media and incubated overnight. Next day, cells were treated with 20 µM CP2, a 
concentration that is non-toxic to cells (Figure 1.8) but leads to the NRF2 activation 
(Figure 4.4). ROS generation was detected using mitosox, a dye that shifts fluorescent 
wavelength upon oxidizing by ROS as shown in Figure 4.7. Cells were incubated with 5 
µM mitosox in HBSS buffer for 10 min at 37°C, followed by 20 µM CP2 treatment for 
90 min at 37°C. After incubation with CP2, cells were trypsinised, collected in PBS + 
5% FBS solution, and analyzed by flow cytometry at 488 nM excitation/580 nM 
emission wavelength. Results were analyzed using Cell quest software (BD biosciences). 
I found that non-toxic concentration of CP2 leads to a generation of ROS. As a control, I 
pre-incubated cells with 2 mM of NAC ((N-acetyl-L-cysteine, a known ROS scavenger) 
for 1 hour before treatment with mitosox. I found that NAC treatment abolished ROS 
generation (Figure 4.8). This experiment demonstrates that CP2 leads to a production of 
sub-lethal levels of ROS in HEPG2 reporter cells, which could lead to the activation of 
NRF2/ARE pathway via mitohormesis without inducing any cellular toxicity.  
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Figure 4.7. Demonstration of FACS analysis using mitosox. 
Dot plot shows selection of the population of cells based on forward and side scattering 
and histogram shows the comparison between mitosox treated and untreated samples as 
controls. 
 
 
 
 
 
Figure 4.8. CP2 leads to a production of ROS in HEPG2 ARE reporter cells. 
ROS generation was measured in HEPG2 ARE reporter cells using mitosox and flow 
cytometry. Graph is the representative of two independent experiments. Data is 
represented as the mean +/- SE of duplicates; t-test is used for the statistics, *, p<0.05, 
***, p < 0.005. 
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4.4. CP2 does not induce a sustainable ROS activation, which is consistent with the 
mitohormetic mechanism 
 
I further determined whether CP2-induced activation of ROS is consistent with the 
mitohormetic mechanism by comparing the kinetics of ROS production induced by CP2 
vs. antimycin in HEPG2 ARE reporter cells. Antimycin, a known complex III inhibitor, 
generates high levels of ROS leading to cell death [64]. Unlike the last experiment where 
mitosox treatment was done prior to CP2 treatment, HEPG2 ARE reporter cells were 
first treated with 20 µM or 50 µM of CP2 for 5, 15, 45 min and 1 hour at 37°C. Cells 
were then incubated with 5 µM mitosox in HBSS for 10 min at 37°C.  After incubation, 
cells were trypsinised, collected in PBS + 5% FBS, and analyzed by flow cytometry at 
488 nM excitation/580 nM emission wavelength. Results were analyzed using Cell quest 
software (BD biosciences). I observed a very different kinetics of ROS production in 
cells treated with CP2 vs. cells treated with antimycin (Figure 4.9). Acute CP2 treatment 
produced transient increase in ROS levels with a rapid decay consistent with the 
signature of ROS production involved in mitohormesis [42]. However, levels of ROS 
induced by antimycin treatment continued to progressively increase over a prolong 
period of time, which eventually results in cell death (Figure 4.9) 
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Figure 4.9. CP2 generates a transient increase in ROS production in HEPG2 ARE 
reporter cells followed by a decay compared to a sustained ROS production in 
antimycin-treated cells.  
HEPG2 ARE reporter cells were treated with CP2 (20 µM) or antimycin (50 µM) for 
indicated time points followed by incubation with mitosox (5 µM) for 10 min, and cells 
were sorted based on fluorescence 488 excitation and 580 emission. Data was 
background corrected and each data point represents mean of three independent 
measurements and bars denote standard error.  
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4.5. Treatment with antioxidants abrogates CP2-induced activation of NRF2 in 
HEPG2 ARE reporter cells 
 
In order to confirm that generation of ROS is essential for the CP2-induced NRF2 
activation, I examined whether a pre-incubation with anti-oxidants that would sequester 
CP2-induced ROS and abolishes CP2 efficacy in HEPG2 reporter cells. HEPG2 reporter 
cells were pre-incubated with 0.5 - 1 mM of trolox or 2 mM of NAC for 1 hour. Cells 
were treated with 20 µM of CP2, and NRF2 activation was assayed 24 hrs later by 
measuring luminescence using the same experimental procedure as described in Figure 
4.3. I found that trolox pre-treatment totally abolished the NRF2 activation, while NAC 
pre-treatment partially reduced the NRF2 activation by CP2 treatment. Difference in the 
activity of trolox and NAC is attributed to the fact that trolox is a direct ROS scavenger; 
however, NAC reduces cellular ROS by inducing synthesis of glutathione. This suggests 
that CP2-induced ROS production is essential for signaling involved in the NRF2 
activation (Figure 4.10). This data provides further support for mitohormetic mechanism 
involved in the CP2-induced activation of NRF2/ARE pathway and protection against 
oxidative stress.  
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Figure 4.10. Anti-oxidant treatment abrogates CP2-induced NRF2 activation.  
HEPG2 ARE reporter cells were pretreated with trolox or NAC, followed by 24-hours 
incubation with 20 µM CP2. Graphs represent two independent experiments. Data is 
represented as Mean +/- SE of triplicates; t-test was used for statistical analysis; *, p < 
0.05, **, p < 0.01, ***, p < 0.005.  
 
 
 
 
 
 
 
 
 
HEPG2 ARE reporter cell 
Cells were pretreated with trolox or NAC followed with 24 hrs incubation 
with or without 20 µM CP2 
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4.6. CP2 induces NRF2 activation in vivo in ARE reporter mice 
 
My previous data generated in ARE reporter cells demonstrated that CP2 induces 
activation of NRF2/ARE pathway. I next validated whether CP2 induces NRF2 
activation in vivo using ARE reporter mice [65]. The schematic diagram representing the 
generation of ARE reporter mice that express a heat stable human alkaline phosphatase 
(hPAP) gene fused with the NRF2 promoter sequence is shown in Figure 4.11.  Male 
and female ARE reporter mice were treated with CP2 (25 mg/kg/day via gavage) for 4 
days. Control mice were gavaged with vehicle. Mice were sacrificed; brain tissue was 
collected. Two to five mg of frozen hippocampus brain tissue was homogenized in 1mL 
TMNC buffer (50 mM Tris pH 7.5, 5 mM MgCl2, 100 mM NaCl, and 4% 3-((3-
cholamidopropyl) dimethylammonio)-1-propanesulfonate (CHAPS). The homogenate 
was freeze-thawed, and 25 μL was added to a white-walled 96 well plate and mixed with 
75 μL of 200 mM diethanolamine (DEA) buffers. Plates were incubated for 20 min at 
65°C to inhibit endogenous phosphatases. Following the addition of 100 μL of substrate 
solution [2X CSPD (Applied Biosystems, catalog# T2041), 2X Emerald reagent 
(Applied Biosystems, catalog# T2115), 5 mM MgCl2, and 150 mM DEA] and 
incubation in the dark for 20 min at room temperature, luminescence was measured 
using a microplate luminometer (Berthold Detection Systems, Pforzheim, Germany) 
with one second integration time. Luminescence values were normalized to protein 
concentration measured using bicinchoninic acid protein assay (Bio-Rad, catalog# 
500012). ARE-hPAP activity was expressed as relative luminescence units (RLU) per 
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mg of protein. I found that CP2 treatment induces NRF2 activation in ARE reporter mice 
compared to vehicle-treated mice (Figure 4.13). These data further confirmed that CP2 
induces transcriptional activation of the ARE pathway in vivo.  
 
 
Figure 4.11. Generation of the ARE reporter mice. 
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Figure 4.12. Schematic experimental procedure for measurement of hPAP activity 
in the brain tissue of ARE reporter mice treated with CP2.  
 52 
 
 
 
Figure 4.13. CP2 induces NRF2 activation in vivo in ARE reporter mice.  
The activity of hPAP was measured by treating brain lysates with chemiluminescent 
alkaline phosphatase substrate. Data was normalized using protein concentration. N=4 
for control mice and n = 2 for CP2-treated mice. Data is presented as Mean +/- SE of 
triplicates; results were analyzed using t-test. ****, p < 0.001.  
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4.7. CP2 protects against oxidative stress in Drosophila via NRF2 activation 
 
To demonstrate that CP2 protects against oxidative stress via NRF2 activation, I 
employed the Drosophila model systems.  Drosophila shares 70% of the genes that cause 
diseases in humans, and those genes can be easily modified for experiments to better 
understand any given molecular mechanism. The short lifespan and growth time to 
maturity make Drosophila an ideal model for performing survival experiments [66]. To 
examine the effect of CP2 treatment on protection against oxidative stress, I divided 
Drosophila into 2 groups consisting of 40 animals. The first group was treated with 2% 
hydrogen peroxide (H2O2) in 10% of sucrose solution. The second group was treated 
with 2% H2O2 and CP2 (25 mg/kg/day) in 10% of sucrose solution. The CP2 
concentration was similar to the concentrations utilized in the previous studies 
demonstrating neuroprotection in mice [62]. I found that flies treated with CP2 survived 
longer compared to vehicle-treated files suggesting that CP2-induced protection against 
oxidative stress is conserved in Drosophila (Figure 4.14). Next, I examined whether 
NRF2 is required for oxidative stress protection in Drosophila by generating NRF2-
RNAi files with reduced expression of NRF2 using GAL4-UAS system as explained in 
the Figure 4.15. For the generation of NRF2-RNAi files elav Gal4 female virgin were 
separated, these files express GAL4 transcription factor with elav promoter, which is 
specific for gene expression in the brain. Virgin files were crossed with male files having 
UAS (GAL4 DNA binding site) upstream of sequence for NRF2 RNAi or attp2 RNAi 
(genetic background control). After strain generation, experiment with these knockdown 
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strains was done within 21 days. Knockdown of NRF2 was confirmed by qPCR from the 
RNA isolated from files head (Figure 4.16). Survival studies were done in NRF2 RNAi 
flies as described previously. Consistent with our previous observations, the protection 
against oxidative stress was lost in Drosophila when NRF2 was knocked down further 
confirming that NRF2 is the key mediator of the CP2-induced mechanism of oxidative 
stress protection (Figure 4.17).  
 
 
 
 
Figure 4.14. CP2 promotes the survival of Drosophila treated with 2% H2O2.  
Graph represents three independent experiments each including 40 files.  
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Figure 4.15. Diagram demonstrating the generation of RNAi Drosophila strain 
using UAS-GAL4 system.  
 
 
 
Figure 4.16. Confirmation of NRF2 expression in NRF2-RNAi Drosophila strain. 
mRNA level of NRF2 in Drosophila was measured in WT males and females files 
compared to NRF2-RNAi (KD) using one step qPCR SYGR kit. RP-49 was used as a 
housekeeping gene for data normalization. Data presented as Mean +/- SEM of 
triplicates. T-test was used for statistical analysis, **, p < 0.01, ***, p<0.005. 
elavGAL4 female 
virgins 
Male RNAi: 
Attp2 or NRF2 
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Figure 4.17. RNAi-mediated knockdown of NRF2 abrogates CP2-induced survival 
of Drosophila treated with 2% H2O2.  
Graph represents three independent experiments each including 40 files. 
 
4.8. CP2 protects against oxidative stress in wild-type mice fed with a high fat diet  
 
Consumption of a high fat diet (HFD) negatively impacts metabolism by altering the 
substrate utilization pathways and leading to extensive oxidative damage, cognitive 
impairment and increased mortality [67, 68]. Specifically, studies have implicated that 
impaired NRF2 signaling and increased oxidative stress as mechanisms underlying 
HFD-induced decline in cognitive performance in the aged brain [69]. Interestingly it 
was found that mice on a HFD+CP2 showed a significantly greater survival rate and the 
lack of cognitive of behavior phenotype compared to the HFD group (Figure 1.8).  All 
animals in HFD group developed multiple tumors confirmed during the postmortem 
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tissue examination while none of the animals in HFD+CP2 group developed tumors. To 
validate that CP2 protection was due to the reduced oxidative damage, I measured level 
of lipid peroxidation in the brain tissue collected from both cohorts of mice. Lipid 
peroxidation is caused by oxidative degradation of lipids. In this process, free radicals 
take electrons from lipids (generally located in membranes), resulting in cell damage. 
Quantification of lipid peroxidation is one the classical way to assess oxidative stress in 
pathophysiological processes. Lipid peroxidation forms reactive aldehydes such as 
malondialdehyde (MDA) and 4-hydroxynonenal (4- HNE) as natural bi-products. I 
measured the end product of lipid peroxidation, MDA, which is one of the most widely 
accepted assays for determining the extent of the oxidative damage. Using MDA 
standard provided in the kit, I found linear dose dependence between MDA 
concentration and absorbance values, which was used for the quantification of MDA in 
brain lysate samples (Figure 4.19). I found that CP2-treated HFD mice showed 
significantly lower lipid peroxidation compared to HFD group further validating that 
CP2 reduced oxidative damage in vivo promoting the survival (Figure 4.20). 
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Figure 4.18. Schematic representation for quantification of MDA in mouse brain 
tissue isolated from a high fat diet mouse treated with CP2. 
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Figure 4.19. Standard curve of MDA  
 
 
 
 
Figure 4.20. CP2 treatment reduces the level of lipid peroxidation in mice fed with 
a HFD.   
Lipid peroxidation was compared in the hippocampus/cortex brain tissue isolated from 
vehicle or CP2-treated mice (n = 5 for each group) fed with a HFD for a year by 
measuring the concentration of malondialdehyde (MDA), a bi-product of lipid 
peroxidation. MDA forms a calorimetric adduct with thiobarbituric acid (TBA). Samples 
were treated according to the instructions provided with the kit (Sigma# MAK085) and 
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absorbance was measured at 532 nm. All experiments were conducted in triplicates. Raw 
data was normalized per protein concentration. T-test was used for statistical analysis, 
***, p < 0.005. 
 
 
4.9. Culturing of neurons from embryonic mouse brain 
 
In order to demonstrate the molecular mechanism of CP2-induced mitohormetic 
response in the context of AD, I will use primary neuronal cells from embryonic mouse 
brain. Primary neuronal cultures represent a powerful model system to study 
mechanisms during a pre-clinical disease development providing an excellent tool for 
disease modeling, and pharmacological and genetic manipulations against 
neurodegenerative diseases. Postmortem analysis of brain tissue from AD patients shows 
the degeneration of cortex and hippocampus areas of the brain [70]. Therefore, I will use 
cortical neuronal cultures for studying the mechanism of CP2-induced neuroprotection. 
Embryonic day 17 (E17) mouse cortical tissue is more difficult to isolate than similar 
rodent tissue due to the size of the sample for dissection. One of the major advantages of 
using embryonic brain is the presence of high proportion of neuronal cell population as 
compared to other cell types like astrocytes and glia. In the protocol described (Methods, 
3.14), I use specific media designed for neuronal growth and careful dissection 
procedure of embryonic cortical tissue to optimize growth of healthy neurons while 
minimizing contamination with other cell types. A brief description of steps involved in 
primary cortical neuronal culture from mouse embryonic brain is shown in Figure 4.21.  
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Figure 4.21. Schematic diagram of isolation of cortical neurons from E17 mouse 
brain. 
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Figure 4.22. Bright field microscopy image of cortical neurons isolated from E17 
mouse brain after 7 days in culture.  
These neurons are fully developed based on the presence of well-developed neuronal 
processes. There is also no visible presence of glia cells and can be used for a variety of 
applications including immunocytochemistry, biochemistry, electrophysiology, calcium 
imaging, protein and/or DNA and RNA isolation. I performed this procedure three times 
using three individual time-pregnant mice together with Dr. Trushina. I also conducted 
three neuronal dissections and platings independently. The image represents results 
generated during my last independent neuronal plating. These cells were used by my 
colleagues to conduct bioenergetics studies required for the resubmission of the 
manuscript reviewed in Neurobiology of Disease.  
 
I will use my ability to culture primary neurons (Figure 4.22) in my future studies to test 
whether CP2 treatment induces activation of NRF2/ARE pathway in these cells. NRF2 
activation will be examined by monitoring its translocation to the nucleus using 
immunostaining. Further, I will also quantify the expression of anti-oxidant genes and 
the anti-oxidant enzymatic level using qPCR and enzyme-linked immunosorbent assay 
(ELISA) respectively in CP2-treated cortical primary neurons. ShRNA targeting NRF2 
will be used to examine whether NRF2 plays a key role for CP2 induced protection 
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against oxidative stress in primary cortical neurons. All these experiments will further 
strengthen my knowledge about CP2-induced neuroprotection and will demonstrate 
activation of mitohormetic mechanism via CP2 in the cells directly affected in AD. 
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5. DISCUSSION 
 
My work enhances the current understanding of the mito-nuclear communication and 
provides evidence that the beneficial reconfiguration of cellular metabolism and 
protective stress response could be triggered using pharmacological agents. My study 
dissected the molecular mechanism and signaling cascade activated by partial complex I 
inhibition using a small molecule CP2. Importantly, I demonstrated that CP2 activated 
the protection against oxidative stress via ROS-related mitohormetic mechanism. 
Through experiments done in isolated mitochondria and on cells, it was established that 
upon binding to complex I, CP2 generates a burst of sub-lethal levels of ROS. Consistent 
with the mitohormetic theory, low levels of ROS initiated signaling inducing activation 
of NRF2, upon CP2 treatment. CP2-induced NRF2 activation was abolished by anti-
oxidant trolox and NAC validating that ROS generation and signaling is essential for the 
initiation of this mito-nuclear communication. However, together with ROS, this 
signaling cascade may be initiated by other factors such as MAP kinase, which also 
known to mediate mitohormesis [42]. Therefore, future studies will address the details of 
this CP2-mediated process. Through my experiments, I validated NRF2 activation via 
CP2 using multiple model systems including the ARE reporter cell lines, and the ARE 
reporter mice. Translational mechanism of CP2 was confirmed by a direct validation of 
target engagement, NRF2 activation and a protection against oxidative stress using 
mitochondria isolated from human postmortem brain, human neuronal cells, mouse 
neurons, Drosophila, and mice fed with a HFD. Reduction of the NRF2 expression in the 
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NRF2-RNAi Drosophila strain showed loss of protection against oxidative stress, 
confirming in vivo that NRF2 activation is the key mechanism for survival induced by 
CP2 under elevated oxidative stress conditions. Since oxidative stress is a main culprit of 
neurodegeneration observed in AD, demonstration that CP2 activates NRF2/ARE 
pathway extends our knowledge of the molecular mechanism involved in CP2-induced 
neuroprotection. Moreover, CP2 induced enhanced survival and reduced the extent of 
oxidative damage in WT ageing mice fed with a HFD, suggests that protective 
mechanisms induced by CP2 could alleviate oxidative damage associated with various 
disease conditions. These results provide a solid foundation to extend CP2 application to 
other human diseases associated with oxidative stress.  
 
From the unpublished results in Dr. Trushina’s lab, it is known that AMPK activation 
and mitohormesis induced by CP2 are two independent mechanisms. One of the 
interesting questions that remain to be addressed is what mechanism, AMPK-dependent 
or NRF2-dependent (Figure 5.1) plays the major role in neuroprotection depending on 
the stage of the disease. During the development of any disorder, levels of ROS 
associated with pathophysiological mechanisms could vary significantly from being low 
at pre-symptomatic stages to increasing significantly at symptomatic phase.  Thus, it is 
possible that CP2-induced mechanism of neuroprotection via NRF2 activation may be 
functional only at the early stages since later in the disease progression increased 
oxidative stress could abolish the positive effect of CP2-ROS signaling. In this case, the 
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AMPK-dependent pathways activated by CP2 could become the key mechanism to 
provide neuroprotection (Figure 5.1).  
 
 
 
Figure 5.1. Molecular mechanism of CP2-induced neuroprotection. 
In the previous study, we found that CP2 inhibits mitochondrial complex I leading to an 
increase in AMP/ATP ratio and activation of AMPK (green pathway). A downstream 
signaling cascade includes the reduction of GSK3β activity; activation of autophagy; 
reduction of levels of Aβ and pTau; restoration of axonal trafficking; increase in the 
levels of BDNF and synaptic proteins that ultimately contribute to neuroprotection. In 
my current study, I demonstrated that partial complex I inhibition also induces a sub-
lethal production of ROS, which via mitohormetic mechanism activates the NRF2-ARE 
pathway. This transcriptional response could account for the observed reduction of 
markers of oxidative stress and prolonged health and lifespan in multiple in vivo models 
of human conditions that include oxidative stress. 
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While the application of partial complex I inhibitors appear to be controversial, a widely 
prescribed FDA approved drug, metformin, that is a partial complex I inhibitor is used to 
treat diabetes, supports the safety of this approach in humans, especially in the elderly 
population. The protective effect of metformin, in part, is also thought to be associated 
with ROS-induced mitohormetic mechanism [71]. However, compared to metformin, 
CP2 penetrates the blood brain barrier and appears not to have numerous molecular 
targets other than mitochondrial complex I. Thus, the development of safe and specific 
complex I inhibitors could provide therapeutic benefits against various diseases linked to 
oxidative stress including AD. Taken together, my results highlight differential and 
complex molecular mechanisms of CP2 that includes the NRF2-dependent stress 
response. Moreover, ROS generation and NRF2 activation are also the key mechanisms 
that are activated during exercise and caloric restriction, demonstrating that complex I 
inhibition via CP2 mimics these molecular signatures and their beneficial outcomes. 
Thus, it is feasible that CP2 could promote health and life span ultimately delaying the 
onset of age-related human diseases.  
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6. CONCLUSIONS 
 
The study revealed that the NRF2 activation via partial complex I inhibition protects 
against oxidative stress in multiple model organisms. The protective effect of NRF2-
ARE pathway activation has shown promising results for the treatment of multiple 
human conditions including AD and obesity [72-74]. Moreover, NRF2 acts as a 
transcriptional factor for more than 200 genes that not only participate in the expression 
of anti-oxidant enzymes but also in the promoting proteasomal and autophagic 
degradation, and anti- inflammatory response. Hence, I identified a novel CP2-induced 
mechanism that could be beneficial for a spectrum of chronic diseases linked to 
progressive oxidative stress, inflammation, and impaired autophagy.  Based on my 
study, Dr. Trushina filed an invention disclosure entitled "Small Molecule Activators of 
the NRF2 Pathway", Mayo Case No. 2017-337. 
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